Hospira


LONDON, October 12, 2010 - Raltitrexed (Tomudex(R)) in combination with cisplatin in the treatment of MPM improves median overall survival compared to treatment with cisplatin alone.[1] With incidence rates expected to double over the next 20 years in many countries[2], new and effective treatments are a welcome addition, concluded an eminent panel of international speakers at a symposium sponsored by Hospira at the 35th congress of the European Society for Medical Oncology (ESMO), Milan.

LEAMINGTON SPA, England, October 4, 2010 - Hospira (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, announced today that Svend Andersen has been named corporate vice president and president, Europe, Middle East and Africa (EMEA).

LONDON, February 22, 2010 - Hospira announced today that the European Committee for Medicinal Products for Human Use (CHMP) has recommended for approval the administration of Retacrit (epoetin zeta) subcutaneously in the nephrology setting.

LEAMINGTON SPA, England - -- Single-Vial Formulation Designed to Improve Safety -- Hospira, Inc.

LAKE FOREST, Illinois - -- Expands Biologics Manufacturing/Commercial Capabilities -- Hospira, Inc.
Older News
S M T W T F S
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
Copyright© 2010 The Gaea Times